Opportunity Information: Apply for RFA CA 10 004
Apply for RFA CA 10 004
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Validation and Advanced Development of Emerging Technologies for Cancer Research (R33)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research.
- This funding opportunity was created on Oct 26, 2009 and posted on Oct 26, 2009.
- Applicants must submit their applications by Sep 30, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,250,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- Eligible applicants include: For profit organizations other than small businesses Public and State controlled institutions of higher education Small businesses Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Non domestic (non U.S.) Entities (Foreign Organizations) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Validation and Advanced Development of Emerging Technologies for Cancer Research (R33) opportunity (Funding Opportunity Number RFA-CA-10-004) is an NCI/NIH funding announcement aimed at pushing promising new molecular and cellular analysis technologies past the early pilot stage and into real, cancer-relevant use. The central focus is technical and analytical validation of an emerging technology in an appropriate biological system that reflects the technology's intended application in cancer research. In this context, "emerging" means the approach has already moved beyond basic tinkering and initial feasibility, shows clear promise, and has proof-of-principle supported by preliminary data, but has not yet been rigorously evaluated in the setting where it is ultimately supposed to function. The expectation is that a successful project will produce a technology that meaningfully accelerates research or application in areas such as cancer biology, treatment, detection and diagnosis, prevention, control and epidemiology, and/or cancer health disparities.
The R33 mechanism is designed for advanced development work where the core concept is already demonstrated and the next critical step is to validate performance and readiness for broader adoption. This makes the program a poor fit for projects that primarily apply established technologies to answer a new biological or clinical question. In other words, the novelty needs to be in the technology itself, not just in what you plan to study with it. Applications that rely on established tools where the "innovation" is mainly the research question are considered non-responsive and can be returned without review. NCI positions this FOA as part of its larger Innovative Molecular Analysis Technologies (IMAT) Program, which supports technology innovation intended to transform cancer research capabilities rather than incrementally improve existing workflows.
From a practical funding standpoint, NCI planned to commit about $2.25 million total in fiscal year 2010 for this announcement, with up to seven awards anticipated. The listed award ceiling is $300,000. There is no cost sharing or matching requirement. The opportunity is categorized as a discretionary grant within health and education related activity categories, and aligns with multiple CFDA program areas covering cancer cause and prevention (93.393), detection and diagnosis (93.394), treatment (93.395), and biology (93.396). The posting and creation date for the announcement were October 26, 2009, with a closing date of September 30, 2010, and an archive date of October 31, 2010.
Eligibility is broad and includes a wide range of organization types: public and state-controlled institutions of higher education, private institutions of higher education, for-profit organizations (including those other than small businesses), small businesses, nonprofits both with and without 501(c)(3) status (other than institutions of higher education), and state governments. It also explicitly includes additional eligible applicants such as federal agencies, U.S. territories or possessions, and non-U.S. (foreign) organizations. For applicants deciding between mechanisms, this R33 runs in parallel with a separate FOA of identical scientific scope that uses the R21 exploratory/developmental mechanism (RFA-CA-10-003). The practical implication is that R21 is positioned for earlier, riskier exploration, while R33 is meant for technologies that already have a demonstrated foundation and are ready for more stringent validation and advanced development work in cancer-relevant systems.
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is titled "Validation and Advanced Development of Emerging Technologies for Cancer Research (R33)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA-CA-10-004.
Which agencies are sponsoring this announcement?
This is an NCI/NIH funding announcement sponsored by the National Cancer Institute (NCI) within the National Institutes of Health (NIH).
What is the main purpose of this R33 opportunity?
The main purpose is to push promising new molecular and cellular analysis technologies beyond the early pilot stage and into real, cancer-relevant use by focusing on technical and analytical validation in an appropriate biological system.
What does "emerging technology" mean in this announcement?
In this context, "emerging" means the approach has moved beyond basic tinkering and initial feasibility, shows clear promise, and has proof-of-principle supported by preliminary data, but has not yet been rigorously evaluated in the setting where it is ultimately intended to function in cancer research.
What type of work is emphasized: discovery science or validation and development?
The emphasis is on technical and analytical validation and advanced development work, not on early feasibility experiments or primarily on using existing tools to pursue a new biological question.
What is meant by "technical and analytical validation" in a cancer-relevant system?
It refers to rigorously evaluating how well the technology performs and whether it is ready for broader adoption when tested in a biological system that reflects the technology's intended application in cancer research.
What kinds of cancer research areas could a successful technology impact?
A successful project is expected to produce a technology that meaningfully accelerates research or application in areas such as cancer biology, treatment, detection and diagnosis, prevention, control and epidemiology, and/or cancer health disparities.
Why is the R33 mechanism being used for this opportunity?
The R33 mechanism is intended for advanced development work where the core concept has already been demonstrated and the next critical step is validating performance and readiness for broader adoption.
What kinds of projects are considered a poor fit for this FOA?
Projects that primarily apply established technologies to answer a new biological or clinical question are a poor fit. The novelty is expected to be in the technology itself, not mainly in the question being studied.
What does it mean if an application is "non-responsive" to this FOA?
Applications that rely on established tools where the "innovation" is mainly the research question (rather than the technology) are described as non-responsive and may be returned without review.
How does this opportunity relate to the IMAT Program?
NCI positions this FOA as part of its Innovative Molecular Analysis Technologies (IMAT) Program, which supports technology innovation intended to transform cancer research capabilities rather than incrementally improve existing workflows.
How much funding did NCI plan to commit, and how many awards were anticipated?
NCI planned to commit about $2.25 million total in fiscal year 2010 for this announcement, with up to seven awards anticipated.
What is the listed award ceiling?
The listed award ceiling is $300,000.
Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement.
What type of grant is this categorized as?
It is categorized as a discretionary grant within health and education related activity categories.
Which CFDA program areas are associated with this opportunity?
The opportunity aligns with multiple CFDA program areas: cancer cause and prevention (93.393), detection and diagnosis (93.394), treatment (93.395), and biology (93.396).
What are the key dates (posting, closing, and archive dates)?
The posting and creation date were October 26, 2009. The closing date was September 30, 2010. The archive date was October 31, 2010.
What types of organizations are eligible to apply?
Eligibility is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, for-profit organizations (including those other than small businesses), small businesses, nonprofits with and without 501(c)(3) status (other than institutions of higher education), and state governments.
Are federal agencies eligible applicants?
Yes. Federal agencies are explicitly included as additional eligible applicants.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are explicitly included as eligible applicants.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The announcement explicitly includes non-U.S. (foreign) organizations as eligible applicants.
Is there a related opportunity using a different NIH mechanism?
Yes. This R33 runs in parallel with a separate FOA of identical scientific scope that uses the R21 exploratory/developmental mechanism (RFA-CA-10-003).
How should an applicant decide between the R21 and the R33 for the same scientific scope?
The R21 is positioned for earlier, riskier exploration. The R33 is meant for technologies that already have a demonstrated foundation and are ready for more stringent validation and advanced development work in cancer-relevant systems.
What is the key expectation for a successful R33 project under this FOA?
The key expectation is that the project will produce a technology that has been validated and advanced to a level that supports broader adoption and meaningfully accelerates cancer research or application in relevant areas.
Browse more opportunities from the same category: Education Health
Next opportunity: Innovative and Early Stage Development of Emerging Technologies in Biospecimen Science (R21)
Previous opportunity: Innovative Technology Development for Cancer Research (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 10 004
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 10 004) also looked into and applied for these:
| Funding Opportunity |
|---|
| Innovative and Early Stage Development of Emerging Technologies in Biospecimen Science (R21) Apply for RFA CA 10 001 Funding Number: RFA CA 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Accelerating the Pace of Drug Abuse Research Using Existing Epidemiology, Prevention, and Treatment Research Data (R01) Apply for PAR 10 018 Funding Number: PAR 10 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Drug Abuse Dissertation Research Epidemiology, Prevention, Treatment, Services, and/or Women and Sex/Gender Differences (R36) Apply for PAR 10 020 Funding Number: PAR 10 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| AIDS Science Track Award for Research Transition (R03) Apply for PAR 10 021 Funding Number: PAR 10 021 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| State and Community Tobacco Control Policy and Media Research (U01) Apply for RFA CA 10 008 Funding Number: RFA CA 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Effectiveness Research on Smoking Cessation in Hospitalized Patients (U01) Apply for RFA HL 10 020 Funding Number: RFA HL 10 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R01) Apply for PA 10 025 Funding Number: PA 10 025 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R21) Apply for PA 10 026 Funding Number: PA 10 026 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (Phased Innovation Award R21/R33) Apply for PAR 10 024 Funding Number: PAR 10 024 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PA 10 023 Funding Number: PA 10 023 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Epigenetic Approaches in Cancer Epidemiology (R01) Apply for PA 10 031 Funding Number: PA 10 031 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Approaches in Cancer Epidemiology (R21) Apply for PA 10 032 Funding Number: PA 10 032 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Transdisciplinary Research in Energetics and Cancer (U54) Apply for RFA CA 10 006 Funding Number: RFA CA 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prioritizing Molecular Targets for Cancer Prevention with Nutritional Combinations (R01) Apply for PA 10 035 Funding Number: PA 10 035 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R01) Apply for PAR 10 038 Funding Number: PAR 10 038 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Dissemination and Implementation Research in Health (R21) Apply for PAR 10 040 Funding Number: PAR 10 040 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Dissemination and Implementation Research in Health (R03) Apply for PAR 10 039 Funding Number: PAR 10 039 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Critical Illness and Injury in Aging (R03) Apply for PA 10 043 Funding Number: PA 10 043 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Critical Illness and Injury in Aging (R01) Apply for PA 10 042 Funding Number: PA 10 042 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Critical Illness and Injury in Aging (R21) Apply for PA 10 044 Funding Number: PA 10 044 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 10 004", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.